Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension
NCT07932145, Phase 4, Not yet recruiting, China National Center for Cardiovascular Diseases
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Early Mineralocorticoid Receptor Antagonist Therapy for Low-Renin Essential Hypertension | ClinicalTrials.gov |
| NCT number | NCT07932145 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Phase 4 | ClinicalTrials.gov |
| Enrollment | 128 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | China National Center for Cardiovascular Diseases | ClinicalTrials.gov |
| Conditions | Hypertension (HTN), Low-Renin Essential Hypertension | ClinicalTrials.gov |
| Interventions | Eplerenone, Telmisartan | ClinicalTrials.gov |
| First posted | 2026-11-12 | ClinicalTrials.gov |
| Last updated | 2026-11-12 | ClinicalTrials.gov |
Registered outcomes 19
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change From Baseline in Mean Daytime Ambulatory Systolic Blood Pressure at Week 12 | Baseline and Week 12 | Change in mean daytime systolic blood pressure, measured in mmHg by 24-hour ambulatory blood pressure monitoring, from baseline to Week 12. Mean daytime systolic blood pressure is the average of all valid daytime systolic readings. A valid recording requires at least 70% of scheduled readings, including at least 20 daytime readings and 7 nighttime readings. Change is calculated as the Week 12 value minus the baseline value; a negative value indicates a reduction in blood pressure. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Office Systolic Blood Pressure | Baseline, Week 12, and Week 24 | Change in seated office systolic blood pressure, measured in mmHg, from baseline to each assessment. Measurements are obtained after at least 5 minutes of seated rest using a standardized upper-arm blood pressure monitor. | ClinicalTrials.gov |
| Secondary | Change From Baseline in Office Diastolic Blood Pressure | Baseline, Week 12, and Week 24 | Change in seated office diastolic blood pressure, measured in mmHg, from baseline to each assessment. Measurements are obtained after at least 5 minutes of seated rest using a standardized upper-arm blood pressure monitor. | ClinicalTrials.gov |
| Secondary | Percentage of Participants Achieving Office Blood Pressure Control | Week 12 and Week 24 | Percentage of participants with seated office systolic blood pressure below 140 mmHg and diastolic blood pressure below 90 mmHg at each assessment. | ClinicalTrials.gov |
| Secondary | Percentage of Participants Achieving an Office Blood Pressure Response | Baseline, Week 12, and Week 24 | Percentage of participants with a reduction from baseline in office systolic blood pressure of at least 10 mmHg, a reduction in office diastolic blood pressure of at least 5 mmHg, or achievement of office blood pressure below 140/90 mmHg. | ClinicalTrials.gov |
| Secondary | Number of Antihypertensive Treatment Adjustments | From randomization through Week 24 | Cumulative number of antihypertensive treatment adjustments per participant, including dose increases, addition of a drug, and discontinuation of a drug. | ClinicalTrials.gov |
| Secondary | Time to First Documented Office Blood Pressure Control | From randomization through Week 24 | Time, measured in weeks from randomization, to the first study visit at which seated office systolic blood pressure is below 140 mmHg and diastolic blood pressure is below 90 mmHg. | ClinicalTrials.gov |
| Secondary | Mean 24-Hour Ambulatory Systolic Blood Pressure | Week 12 and Week 24 | Mean systolic blood pressure, measured in mmHg, calculated from all valid readings during 24-hour ambulatory blood pressure monitoring at each assessment. | ClinicalTrials.gov |
| Secondary | Mean 24-Hour Ambulatory Diastolic Blood Pressure | Week 12 and Week 24 | Mean diastolic blood pressure, measured in mmHg, calculated from all valid readings during 24-hour ambulatory blood pressure monitoring at each assessment. | ClinicalTrials.gov |
| Secondary | Mean Nighttime Ambulatory Systolic Blood Pressure | Week 12 and Week 24 | Mean systolic blood pressure, measured in mmHg, calculated from all valid nighttime readings during ambulatory blood pressure monitoring at each assessment. | ClinicalTrials.gov |
| Secondary | Mean Nighttime Ambulatory Diastolic Blood Pressure | Week 12 and Week 24 | Mean diastolic blood pressure, measured in mmHg, calculated from all valid nighttime readings during ambulatory blood pressure monitoring at each assessment. | ClinicalTrials.gov |
| Secondary | Mean Daytime Ambulatory Diastolic Blood Pressure | Week 12 and Week 24 | Mean diastolic blood pressure, measured in mmHg, calculated from all valid daytime readings during ambulatory blood pressure monitoring at each assessment. | ClinicalTrials.gov |
| Secondary | Antihypertensive Medication Burden at Achievement of Target Office Blood Pressure | At achievement of target office blood pressure during the 24-week treatment period | Total antihypertensive medication burden required to achieve office blood pressure below 140/90 mmHg, expressed in World Health Organization defined daily dose equivalents. For each drug, the prescribed daily dose is divided by its defined daily dose, and the resulting values are summed across drugs. | ClinicalTrials.gov |
| Other | Change From Baseline in Left Ventricular Mass Index | Baseline and Week 24 | Change in echocardiographically measured left ventricular mass indexed to body surface area, expressed in g/m². | ClinicalTrials.gov |
| Other | Change From Baseline in Left Atrial Volume Index | Baseline and Week 24 | Change in left atrial volume indexed to body surface area, measured by echocardiography and expressed in mL/m² | ClinicalTrials.gov |
| Other | Change From Baseline in Urinary Albumin-to-Creatinine Ratio | Baseline and Week 24 | Change in urinary albumin-to-creatinine ratio, calculated by dividing urinary albumin concentration by urinary creatinine concentration | ClinicalTrials.gov |
| Other | Change From Baseline in Plasma Aldosterone Concentration | Baseline and Week 24 | Change in plasma aldosterone concentration, measured using a standardized chemiluminescent immunoassay. | ClinicalTrials.gov |
| Other | Change From Baseline in Direct Renin Concentration | Baseline and Week 24 | Change in direct renin concentration, expressed in mU/L and measured using the DiaSorin LIAISON chemiluminescent immunoassay | ClinicalTrials.gov |
| Other | Change From Baseline in Aldosterone-to-Renin Ratio | Baseline and Week 24 | Change in the ratio of plasma aldosterone concentration to direct renin concentration | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 5
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)